Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Dr. Falk Pharma GmbH clinical trials
The registry lists 39 studies whose lead sponsor is Dr. Falk Pharma GmbH. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 7, 2026.
Keep track of what changes. Save the Dr. Falk Pharma GmbH studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Dr. Falk Pharma GmbH.
- Dr. Falk Pharma GmbH39 studiesSame company
Something wrong?
Focus areas
Conditions Dr. Falk Pharma GmbH leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 39 of 39.
- Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac DiseaseRecruitingNCT07298343Phase 2
- Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)Not yet recruitingNCT06886360Phase 3
- Norursodeoxycholic Acid vs. Placebo in NASHRecruitingNCT05083390Phase 2
- Different Doses of Naronapride vs. Placebo in GastroparesisCompletedNCT05621811Phase 2
- Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoEActive, not recruitingNCT06596252Phase 3
- norUrsodeoxycholic Acid vs Placebo in PSCActive, not recruitingNCT03872921Phase 3
- Different Doses of ZED1227 vs. Placebo in NAFLDCompletedNCT05305599Phase 2
- Mesalazine Oral Suspension in Active Eosinophilic EsophagitisCompletedNCT05488405Phase 2
- Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic EsophagitisCompletedNCT02493335Phase 3
- Budesonide for Induction of Remission in Incomplete Microscopic ColitisCompletedNCT02142634Phase 3
- Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)TerminatedNCT00746486Phase 3
- Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)CompletedNCT02280629Phase 3
- Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary CirrhosisCompletedNCT01510860Phase 4
- Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune HepatitisCompletedNCT00838214Phase 2/3
- Pharmacokinetic Investigation of UDCA in Bile and SerumCompletedNCT00529009Phase 1
- Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative ProctitisCompletedNCT01966783Phase 2
- Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's DiarrhoeaCompletedNCT01208922Phase 3
- Budesonide 9 mg Capsules in Active UCCompletedNCT02550418Phase 2
- Budesonide Versus Mesalazine Versus Placebo in Lymphocytic ColitisCompletedNCT01209208Phase 3
- Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated DiverticulitisCompletedNCT01847664Phase 2
- Mesalazine Granules vs. Placebo for the Prevention of Recurrence of DiverticulitisTerminatedNCT00695643Phase 3
- Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of DiverticulitisTerminatedNCT01038739Phase 3
- Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative ColitisTerminatedNCT02142725Phase 3
- Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic EsophagitisCompletedNCT02434029Phase 3
- Norursodeoxycholic Acid in the Treatment of Primary Sclerosing CholangitisCompletedNCT01755507Phase 2
- TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)CompletedNCT01745770Phase 3
- SOIBD Collagenous Colitis Maintenance StudyCompletedNCT01278082Phase 3
- Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled StudyCompletedNCT01627262Phase 2
- OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative ColitisCompletedNCT00449722Phase 3
- Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic EsophagitisCompletedNCT02280616Phase 2
- Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)CompletedNCT00887263Phase 3
- Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's DiseaseCompletedNCT01279577Phase 2
- 9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's DiseaseCompletedNCT01086553Phase 3
- Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous ColitisCompletedNCT00450086Phase 3
- Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)CompletedNCT00300118Phase 3
- Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus MesalazineCompletedNCT00946946Phase 3
- Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)CompletedNCT00747110Phase 3
- Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)CompletedNCT00746447Phase 3
- Budesonide Foam Versus Placebo for Prevention of Acute Radiation ProctitisTerminatedNCT00828230Phase 2